SCHEMBL18486231

SCHEMBL18486231

c1cc2ccc3ccc(-c4ncnc5nc[nH]c45)c4ccc(c1)c2c34

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR3E A5X5Y0 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ HTR3B O95264 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ HTR3A P46098 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ HTR3C Q8WXA8 1/20 0.44
▸ PIK3CA P42336 3/20 0.43
▸ AKT2 P31751 7/20 0.42
▸ PIK3CG P48736 2/20 0.42
▸ PIK3CB P42338 1/20 0.42
▸ PRKACA P17612 3/20 0.41
▸ PRKACG P22612 3/20 0.41
▸ PRKACB P22694 3/20 0.41
▸ LMNA P02545 2/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ MTOR P42345 2/20 0.40
▸ CDC7 O00311 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18486241 0.78 PIK3CA (0.46) HTR3EMEN1HTR3BMAPTHTR3A
SCHEMBL18486229 0.78 PARP1 (0.34) MEN1MAPTKMT2ALMNAMAPK1
Pyrene SCHEMBL991876 0.75 PI4KA (0.71) HTR3EMEN1HTR3BMAPTHTR3A
SCHEMBL7027583 0.70 MAPT (0.54) MEN1MAPTKMT2APIK3CAAKT2
SCHEMBL28765140 0.69 AKT2 (0.52) PIK3CAAKT2PIK3CGPIK3CBPRKACA
SCHEMBL2938675 0.67 AKT2 (0.70) AKT2PRKACAPRKACGPRKACBCDC7
SCHEMBL29413360 0.67 ALDH1A1 (0.61) MEN1MAPTKMT2AMAPK1
SCHEMBL29814212 0.67 ALDH1A1 (0.61) MEN1MAPTKMT2AMAPK1
SCHEMBL2124728 0.67 ALDH1A1 (0.61) MEN1MAPTKMT2AMAPK1
SCHEMBL30862619 0.66 PI4KA (0.55) AKT2PRKACAPRKACGPRKACBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3130597-B1 OLIGONUCLEOTIDE HAVING A NON-NATURAL NUCLEOTIDE AT THE 5'-TERMINAL KYOWA KIRIN CO LTD (JP) 2021-11-10 — — EP disclosed
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-07-09 — — US disclosed
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-12-14 — — US disclosed
EP-3130597-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF Kyowa Hakko Kirin Co., Ltd. (JP) 2017-02-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof RNGTT, UPF1, NSUN3 HTR3E 972/4885MEN1 3865/4885HTR3B 693/4885
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF RNGTT, UPF1, NSUN3 HTR3E 916/4885MEN1 3871/4885HTR3B 674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback